The anti-diabetic drug metformin regulates T-cell responses to immune activation and is proposed to function by regulating the energy-stress-sensing adenosine-monophosphate-activated protein kinase (AMPK). However, the molecular details of how metformin controls T cell immune responses have not been studied nor is there any direct evidence that metformin acts on T cells via AMPK. Here, we report that metformin regulates cell growth and proliferation of antigen-activated T cells by modulating the metabolic reprogramming that is required for effector T cell differentiation. Metformin thus inhibits the mammalian target of rapamycin complex I signalling pathway and prevents the expression of the transcription factors cMyc and hypoxia-inducible factor 1 alpha. However, the inhibitory effects of metformin on T cells did not depend on the expression of AMPK in T cells. Accordingly, experiments with metformin inform about the importance of metabolic reprogramming for T cell immune responses but do not inform about the importance of AMPK.
Introduction
T lymphocytes respond to pathogens by differentiating to effector subpopulations that mediate the protective immune response. Effector T cells strikingly increase their cellular uptake of multiple nutrients including glucose, amino acids and transferrin. They also swap from metabolising glucose primarily through oxidative phosphorylation to become highly glycolytic [1] [2] [3] [4] . The changes in effector T cell metabolism are important as judged by the consequences of inhibiting key metabolic regulators. For example, the serine/threonine kinase mTORC1 (mammalian Target Of Rapamycin Complex 1) integrates inputs from nutrients, antigen and cytokine receptors to link T cell metabolism and T cell differentiation [5] . mTORC1 thus controls expression of cytolytic effector molecules, chemokine and adhesion receptors in effector T cells [3, 6] and controls effector-memory cell transition [7, 8] .
One other regulator of T cell differentiation is the adenosinemonophosphate (AMP)-activated protein kinase (AMPK) [9, 10] . AMPK is phosphorylated and activated by liver kinase B1 (LKB1) in response to energy stress and functions to enforce quiescence to restore energy balance in cells [11] . In T lymphocytes, AMPK is important for the transition of effector T lymphocytes to memory T cells during the contraction phase of the immune response [10] . Hence as inflammatory signals fade during the resolution of immune responses, signalling via AMPK allows T effector cells to resume a metabolically quiescent state so that they persist to produce accelerated responses upon secondary infection [10] .
The idea that AMPK is an important regulator of T cell functions has been strengthened by the observations that metformin, a drug that activates AMPK, inhibits the production of effector T lymphocytes and promotes the production of memory T cells [12] [13] [14] . The anti-inflammatory actions of metformin extend to its ability to suppress the development of autoimmune diseases in mouse models [12, 15] . Moreover, metformin has been shown to inhibit the proliferation and survival of acute myeloid leukaemic [16] and T-cell acute lymphoblastic leukaemic cells [17, 18] .
Metformin activates AMPK because this drug inhibits respiratory chain complex I and thereby causes an increase in the cellular AMP/ATP ratio [19] , leading to the phosphorylation and activation of AMPK via LKB1 [11] . The effects of metformin on T cell function are thus invariably interpreted in terms of its ability to activate AMPK. Indeed, current models of AMPK function in immune cells are based largely on experiments with metformin. There is, however, a critical caveat because metformin only indirectly activates AMPK, because it inhibits respiratory chain complex I and thereby causes an increase in cellular AMP/ ATP ratio. Metformin thus has many effects on cell metabolism that are not mediated by AMPK [20] [21] [22] . Indeed, even the actions of metformin in the liver that underpin its efficacy in the treatment of diabetes have been shown to be AMPK-independent [20, 22] .
The potential for AMPK-independent actions of metformin does not seem to be considered in any of the immunological studies that use this drug to manipulate cellular immune responses. Consequently, the regulatory effects of metformin in the immune system are used to model the role of AMPK. Accordingly, the objective of the present study is to explore the relevance of AMPK in mediating the immune-regulatory effects of metformin in T lymphocytes. We compared the effects of metformin on antigen receptor and cytokine regulated responses in wild type and AMPKa1 null CD8 T cells. We found that metformin controls key metabolic pathways in T cells and hence controls T cell growth and proliferation. However, the immune regulatory effects of metformin have no requirement for expression of AMPK in T cells. Experiments with metformin thus inform about the importance of metabolic signalling for T cell biology but do not inform about the role of AMPK. 
Materials and Methods

Ethics Statement
Lymphocyte Culture
CD8
pos lymphocytes were isolated by autoMACS using the CD8a+ T cell Isolation Kit II (Miltenyi Biotec, Germany). CTL cultures from OT-I TCR + mice were generated as previously described [3, 10, 23] . Where outlined, cultures were also treated with 10 mM metformin (1,1-dimethylbiguanide hydrochloride; Sigma-Aldrich). Where shown, freshly isolated lymphocyte cultures were maintained in 5 ng mL 21 IL-7 (Peprotech) for indicated periods of time. For proliferation assays, lymph node suspensions from OT-I TCR + mice were labelled with 5 mM CFSE or Cell Tracer Violet (Molecular Probes) and TCR activated with 1 nM SIINFEKL in the absence or presence of 10 mM metformin for up to 72 h.
Immunoblotting
Lymphocytes were lysed in F buffer (1610 7 cells mL 21 ) and subjected to immunoblot analysis as described previously [3, 10] . Total ACC and ACC S79 were detected by bi-fluorometric analysis using the Odyssey LICOR system and ImageJ software was used for integral signal quantification. Anti-AMPKa1 and anti-ACC S79 were kindly provided by Grahame Hardie, University of Dundee, U.K. Anti-Smc1 was purchased from Bethyl Laboratories Inc and anti-Hif1a was obtained from R&D Systems. Anti-Glut1 was a gift from Geoff Holman, University of Bath, U.K. [19, 24] . All other antibodies for immunoblotting were obtained from Cell Signaling Technology. Antigens were detected using suitable HRP-conjugated secondary antibodies and enhanced chemoluminescence.
Flow Cytometry
Accurate cell counts of lymphocyte cultures were taken by using AccuCheck counting beads (Life Technologies, UK) or, alternatively, by direct event counts against volumetric flow rate on FACSVerse (Beckton Dickinson). Antibodies used for flow cytometry were conjugated to fluorescein-isothiocyanate (FITC), phycoerythrin (PE), peridinin-chlorophyll protein (PerCP)-Cy.5.5, PE-Cy7, allophycocyanin (APC), APC-eFluor 780 or Alexa Fluor 647 and were obtained from BD Pharmingen or eBiosciences unless otherwise stated: anti-CD8a (clone 53-6.7), anti-CD25 (clone PC61), anti-CD44 (clone IM7), anti-CD69 (clone H1.2F3), CD71 (clone C2), CD98 (clone RL388; Biolegend). Intracellular levels of S6 protein phosphorylated on S235 and S236 (S6 S235/6 ) were detected by using Alexa-Fluor-647-conjugated anti-S6 S235/6 (4851; Cell Signalling Technologies) as previously described [23] . Following incubation with antibodies, cells were washed and resuspended in FACS buffer. Samples were analysed using LSR II Fortessa or FACSVerse (Becton Dickinson). A minimum of 1610 4 ungated events were acquired and stored. Data files were processed using the FlowJo software V9.6.4 (Treestar) for Mac OS. Live cells were gated according to their forward and side scatters.
Metabolic Assays
Glucose uptake and lactate output assays were performed as previously described [3, 23] .
Statistical Analysis
Quantified data were statistically evaluated using non-parametric Mann-Whitney test or two-way ANOVA with Bonferroni's comparisons test, where specified. Bar graphs were drawn as mean 6 standard deviation (SD). GraphPad Prism 6 for Mac OS X was used for statistical analysis and generation of bar graphs of quantified data.
Results and Discussion
Metformin regulates glucose uptake and mTORC1 activity in T cells
To understand the effects of metformin on T cells, CD8
+ OT-I TCR + T cells were activated by the T cell antigen receptor (TCR) ligand SIINFEKL in the absence or presence of 10 mM metformin. T cells respond to antigen receptor triggering by upregulating expression of the adhesion molecule CD69 and upregulating expression of CD98, a key subunit of System L amino acid transporters ( Figure 1A) . Antigen activated T cells exposed to metformin also up-regulated expression of CD69 and CD98 and their response was comparable to that of control antigen receptor activated T cells ( Figure 1A) . Metformin treated T cells also respond to TCR engagement by increasing expression of the interleukin-2 receptor (IL-2R) a chain CD25 and the hyaluronan adhesion receptor CD44 ( Figure 1A ). However metformin treatment caused a modest decrease in the expression of these receptors compared to the normal response of antigen activated T cells ( Figure 1A) . Moreover, a striking effect was that metformintreated T cells did not undergo normal blastogenesis in response to TCR engagement ( Figure 1B) .
T cells respond to antigen by increasing glucose uptake and by making a switch from oxidative phosphorylation to aerobic glycolysis [3, 25, 26] . Metformin-treated antigen receptor activated T cells showed reduced glucose uptake but increased lactate output compared to control antigen-activated cells ( Figure 1C  and D) . In T cells, glucose uptake is mediated by the glucose transporter Glut1, whose expression is regulated by the transcription factors c-Myc and hypoxia-inducible factor-1a (HIF-1a) [3, 25] . Metformin treatment blocked TCR-induced expression of c-Myc, HIF-1a and Glut1 ( Figure 1E ). We also examined the impact of metformin on the activity of mTORC1 in TCRactivated T cells. mTORC1 activity was monitored by assessing the phosphorylation of the mTORC1 substrate sequence in p70 S6-Kinase 1 (p70S6K1 T389 ) and phosphorylation of the S6K substrate sequence in the S6 ribosomal subunit (S6 S235/6 ). Figure 1E shows that metformin treatment inhibited TCRinduced phosphorylation of p70S6K T389 and S6 S235/6 . Metformin-treated cells also expressed lower levels of S6 protein, suggesting that metformin also decreased TCR-induced ribosomal biogenesis ( Figure 1E) . One other key metabolic change that normally accompanies T cell activation is the induction of pos cells were analysed by flow cytometry (A) for TCR-induced changes in the surface expression of CD25 (interleukin-2 receptor a chain), CD44 (hyaluronan adhesion receptor), CD69 (early T cell activation) and CD98 (heavy chain of the system L transporter) and (B) for changes in cell size using forward and side scatter (FSC and SSC, respectively). (C, D) TCR-activated CD8 pos T cells were purified by negative selection and then cultured for 3-4 h and subjected to (C) radio-labelled glucose ([ 3 H] 2-DG) uptake or (D) lactic acid production assays. Bar graphs display pooled data from three independent mice in triplicate analysis and show mean 6 SD. Statistical analysis was MannWhitney test, where **p,0.01 and ***p,0.001. (E) Purified CD8 pos T cells from IL-7-treated or TCR-activated lymph nodes were rested in conditioned medium (that is medium retained from IL-7-treated or TCR-activated whole lymph node culture) for 3-4 h and then lysed at 1610 7 cells mL 21 for subsequent immunoblot analysis of indicated phospho-and pan-proteins. Immunoblots are representative of two independent mice. (F) CD8 pos cells were analysed for the expression of CD71 (transferrin receptor) following TCR activation for 20 h. Bi-parametric plots and histograms are representative of at least three independent experiments. doi:10.1371/journal.pone.0106710.g001 expression of the transferrin receptor CD71. Figure 1F shows that TCR-induced up-regulation of CD71 was severely reduced in cells treated with metformin compared to control antigen receptor activated cells.
AMPK-independent actions of metformin in T cells
The actions of metformin on lymphocytes are interpreted to reflect the impact of this drug on AMPK [13] . To directly examine the role of AMPK as the effector of metformin, we compared the effects of metformin on wild type versus AMPK-null T cells. T cells only express the AMPKa1 catalytic isoform [10, 27] . Accordingly, we could study the role of AMPK as a mediator of metformin actions using isolated AMPKa1 null T cells from mice with a T cell selective deletion of AMPKa1 (CD4Cre + AMPKa1 fl/ fl (AMPKa1 null ) mice) [10, 28] . The data in Figure 2 show that metformin blocked T cell blastogenesis and proliferation in both wild type and AMPKa1 null naïve TCR-triggered T cells (Figure 2A and B) . Hence, the ability of metformin to block T cell growth and proliferation is not mediated by AMPK.
In further experiments, we compared the effects of metformin on IL-2 induced growth and proliferation of AMPKa1-sufficient and -deficient cytotoxic T cells (CTL). IL-2 controls effector T cell differentiation and antigen-receptor-activated CD8 T cells cultured in IL-2 clonally expand and differentiate to CTL [29] . The rationale for looking at the effects of metformin on IL-2 signalling in CTL is that these cells have high rates of glucose uptake and are highly glycolytic and it is not clear if they would show any sensitivity to metformin, which inhibits cellular metabolism through the inhibition of respiratory chain complex I. Moreover, IL-2 is a key pro-inflammatory cytokine for effector CTL differentiation in vivo [29] and hence understanding the impact of metformin on IL-2 responses in T cells might give insights as to why this drug can modify effector/memory T cell differentiation in vivo. Figure 2C addresses this issue and shows that metformin inhibits IL-2-induced clonal expansion of CTL. Moreover, the inhibitory effects of metformin were comparable in AMPKa1-sufficient and -deficient CTL.
Metformin did not inhibit glucose uptake by CTL but significantly increased lactate output of CTL in a response that was not dependent on the expression of AMPKa1 in CTL ( Figure 2D) . We have shown previously that AMPKa1 can function to terminate mTORC1 activity in CTL under conditions of energy stress [10] . Figure 3 shows that control and AMPKa1 null CTL had high levels of mTORC1 activity as assessed by the levels of IL-2-dependent phosphorylation of p70S6K on T389 and T421/S424, S6 S235/6 and S6 S240/4 . Strikingly, metformin inhibited mTORC1 signalling equally in AMPKa1-sufficient and -deficient CTL ( Figure 3A) . Further, we have assessed levels of S6 S235/6 in control and AMPK null CTL upon metformin treatment using flow cytometry providing a means of measuring indirectly metformin effects on mTORC1 signalling and compared this with the treatment of CTL using the mTORC1 inhibitor rapamycin. The data in Figure 3B reveal that metformin treatment decreased S6 S235/6 phosphorylation equally in control and AMPK null CTL and to a comparable effect as rapamycin treatment of CTL. Hence, although metformin could activate AMPK in T cells ( Figure 3C ), AMPKa1 does not mediate the inhibitory actions of metformin on mTORC1 activity in T cells.
Conclusion
The present study shows that metformin has direct effects on T cells to block their blastogenesis and proliferation. Metformin acts to suppress these T cell responses, because it blocks key metabolic changes triggered by engagement of the T cell antigen receptor complex. Metformin was also able to supress the proliferative response induced by the cytokine IL-2 in effector cytotoxic T cells. Metformin-treated antigen receptor activated T cells have complex metabolic defects and fail to increase glucose uptake or express transferrin receptors. This effect of metformin on T cell metabolism could be explained in part by its effect on mTORC1 activity [3] but could also reflect that metformin-treated T cells cannot respond to T cell activation to normally express the transcription factors c-Myc and HIF-1a. These are key transcription factors that control the expression of nutrient transporters in T cells [3, 25] .
It has been shown that metformin treatment can promote memory T cell responses [13] and it was assumed that the immune-modulatory actions of metformin reflected the role of AMPK in memory T cells. Indeed, subsequent studies showed that AMPK is required for the formation of CD8 memory T cells as it restrains mTORC1 activity under conditions of glucose energy stress [10] . Nevertheless, despite the reciprocal effects of metformin treatment and AMPK deletion on memory T cell responses there has been no direct assessment of the role of AMPK as a mediator of metformin action in T cells. The current study addresses this issue and shows that metformin has potent effects as an immunosuppressant independently of AMPK. The present results thus afford the insight that experiments with metformin inform about the importance of metabolic signalling for T cell biology but do not inform about the role of AMPK. How does metformin exert its immune-modulatory actions if not via AMPK? In this context, the direct target for metformin is respiratory chain complex I. It is known that naïve T cells are dependent on oxidative phosphorylation for ATP generation and hence the sensitivity of these cells to metformin would reflect this. It was intriguing that the present data show that effector CTL, cells that are highly glycolytic, were also sensitive to metformin. Thus, although the immune activation of T cells is associated with a switch to glycolysis, the present results argue that metabolic pathways channelled via respiratory chain complex I are important for both naïve and effector T cells.
